Publications
Detailed Information
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rhee, Jiyoung | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Park, In Ae | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Kim, Tae-You | - |
dc.date.accessioned | 2009-05-27T23:15:53Z | - |
dc.date.available | 2009-05-27T23:15:53Z | - |
dc.date.created | 2020-12-22 | - |
dc.date.created | 2020-12-22 | - |
dc.date.issued | 2008-10-23 | - |
dc.identifier.citation | BMC Cancer, Vol.8, p. 307 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.other | 119545 | - |
dc.identifier.uri | https://hdl.handle.net/10371/3964 | - |
dc.description.abstract | Background: Triple-negative (TN) breast cancer, which is defined as being negative for the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER-2), represents a subset of breast cancer with different biologic behaviour. We investigated the clinicopathologic characteristics and prognostic indicators of lymph node-negative TN breast cancer. Methods: Medical records were reviewed from patients with node-negative breast cancer who underwent curative surgery at Seoul National University Hospital between Jan. 2000 and Jun. 2003. Clinicopathologic variables and clinical outcomes were evaluated. Results: Among 683 patients included, 136 had TN breast cancer and 529 had non-TN breast cancer. TN breast cancer correlated with younger age (< 35 y, p = 0.003), and higher histologic and nuclear grade (p < 0.001). It also correlated with a molecular profile associated with biological aggressiveness: negative for bcl-2 expression (p < 0.001), positive for the epidermal growth factor receptor (p = 0.003), and a high level of p53 (p < 0.001) and Ki67 expression (p < 0.00). The relapse rates during the follow-up period (median, 56.8 months) were 14.7% for TN breast cancer and 6.6% for non-TN breast cancer (p = 0.004). Relapse free survival (RFS) was significantly shorter among patients with TN breast cancer compared with those with non-TN breast cancer (4-year RFS rate 85.5% vs. 94.2%, respectively; p = 0.001). On multivariate analysis, young age, close resection margin, and triple-negativity were independent predictors of shorter RFS. Conclusion: TN breast cancer had higher relapse rate and more aggressive clinicopathologic characteristics than non-TN in node-negative breast cancer. Thus, TN breast cancer should be integrated into the risk factor analysis for node-negative breast cancer. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BioMed Central | - |
dc.title | The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1186/1471-2407-8-307 | - |
dc.citation.journaltitle | BMC Cancer | - |
dc.identifier.wosid | 000260902900002 | - |
dc.identifier.scopusid | 2-s2.0-55949130920 | - |
dc.citation.startpage | 307 | - |
dc.citation.volume | 8 | - |
dc.identifier.sci | 000260902900002 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Han, Wonshik | - |
dc.contributor.affiliatedAuthor | Park, In Ae | - |
dc.contributor.affiliatedAuthor | Noh, Dong-Young | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | BASAL-LIKE SUBTYPE | - |
dc.subject.keywordPlus | DNA-REPAIR DEFECT | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | ESTROGEN-RECEPTOR | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordPlus | PHENOTYPE | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.